Physiomics uses Virtual Tumour and other industry standard technologies to predict the effects of cancer treatment regimes for the biopharma industry.

How can we help you?

Solve cancer drug development challenges

Optimise combination regimens, manage drug resistance, scale up from mouse to human, predict immune-oncology effects

Learn more

See our range of cancer modelling experience

Find out more about drug targets, drug types and cell lines where we have significant experience

Learn more

Learn about Virtual Tumour

Flexible in-silico cell-cycle based model combining PK and PD effects to predict cancer growth inhibition.

Learn more

Any other questions?

If you don’t see what you need here, please contact us by clicking on the link below.

Contact Us

News & publications

Contract award

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k…

Physiomics expands technical team

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist. Click here to read in full.

Trading update

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm…